Carrick Therapeutics, a Dublin-headquartered biopharma firm, has landed a $35 million investment from Pfizer as it also confirmed the final closure of a $25 million Series C funding round.
The company which is developing pioneering treatments to defeat some of the most aggressive cancers was founded by Elaine Sullivan, a former vice-president for research and development at both Eli Lilly and AstraZeneca, in 2016.
Resumimos esta notícia para que você possa lê-la rapidamente. Se você se interessou pela notícia, pode ler o texto completo aqui. Consulte Mais informação: